{
  "item1": "Marketing, Sales Distribution Capabilities AbbVie utilizes combination dedicated commercial resources, regional commercial resources distributorships market, sell distribute its products worldwide. AbbVie directs its primary marketing efforts toward securing prescription, recommendation, its brand products physicians, external experts other health care providers. Managed care providers (for example, health maintenance organizations pharmacy benefit managers), hospitals state federal government agencies (for example, State Medicaid programs, United States Department Veterans Affairs United States Department Defense) also important customers. AbbVie also markets directly consumers themselves, although United States many company's products must sold pursuant prescription.",
  "item7": "2025 Strategic Objectives AbbVie's mission discover develop innovative medicines products solve serious health issues today address medical challenges tomorrow while achieving top-tier financial performance through outstanding execution. AbbVie intends execute its strategy advance its mission number ways, including: (i) maximizing benefits diversified revenue base multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength international infrastructure across therapeutic areas ensuring strong commercial execution new product launches; (iii) continuing invest expand its pipeline support opportunities immunology, oncology, aesthetics, neuroscience eye care well continued investment key on-market products; (iv) generating substantial operating cash flows support investment innovative research development, return cash shareholders via strong growing dividend while also continuing repay debt. addition, AbbVie anticipates several regulatory submissions data readouts key clinical trials next 12 months. AbbVie expects achieve its strategic objectives through: Maximizing revenue growth key on-market products, including Skyrizi, Rinvoq, Venclexta, Elahere, Vraylar, Ubrelvy, Qulipta, Vyalev/Produodopa, Botox Juvederm Collection.",
  "item2": "ITEM 2. MANAGEMENT’S DISCUSSION ANALYSIS FINANCIAL CONDITION RESULTS OPERATIONS following discussion analysis financial condition AbbVie Inc. (AbbVie company) September 30, 2025 December 31, 2024 results operations three nine months ended September 30, 2025 2024. commentary should read conjunction Condensed Consolidated Financial Statements accompanying notes appearing Item 1, “Financial Statements Supplementary Data.” EXECUTIVE OVERVIEW AbbVie global, diversified research-based biopharmaceutical company positioned success comprehensive product portfolio leadership positions across immunology, neuroscience, oncology, aesthetics eye care."
}